Oloker Therapeutics
Oloker Therapeutics is a biotechnology start-up dedicated to discovering, developing, and commercializing cellular therapies for cardiovascular diseases. Their mission is to bring innovative cellular therapies to address unmet clinical needs, improving patient prognosis and quality of life through extensive scientific research and expertise in cardiovascular medicine. They develop proprietary cardiac-derived progenitor cell products aimed at curing various cardiovascular conditions, with a focus on angiogenesis and tissue repair. Their technology originates from collaboration between scientists and physicians, following a bench-to-bedside approach.
Industries
Nr. of Employees
small (1-50)
Oloker Therapeutics
Patents
Method for the isolation of subpopulations of cardiac progenitor cells and related uses in the medical field
US-12006514-B2
View Details
Method for the isolation of subpopulations of cardiac progenitor cells and related uses in the medical field
US-12006514-B2
View DetailsProducts
Cardiac progenitor cell therapy platform (product-by-process)
A product-by-process platform comprising methods for selection and expansion of human cardiac progenitor cells and a GMP-compliant manufacturing workflow to produce a cell therapy intended for intramyocardial delivery to ischemic myocardium.
Cardiac progenitor cell therapy platform (product-by-process)
A product-by-process platform comprising methods for selection and expansion of human cardiac progenitor cells and a GMP-compliant manufacturing workflow to produce a cell therapy intended for intramyocardial delivery to ischemic myocardium.
Services
Partnerships for preclinical development, translational studies and advancement of cardiac cell therapy candidates toward clinical evaluation.
Support for GMP translation of cell products and preparation of regulatory dossiers for early-phase clinical authorization.
Partnerships for preclinical development, translational studies and advancement of cardiac cell therapy candidates toward clinical evaluation.
Support for GMP translation of cell products and preparation of regulatory dossiers for early-phase clinical authorization.
Expertise Areas
- Cell therapy development
- Cardiovascular regenerative medicine
- GMP cell manufacturing and scale-up
- Preclinical efficacy and safety testing
Key Technologies
- Cell isolation and subpopulation selection methods
- Scalable cell expansion processes
- GMP-compliant manufacturing for cell therapies
- Potency assays and batch release testing